Main Menu
News language and date
Language or country:
Date:
Analysis over time
Wednesday, October 19, 2005
Wonderdrug is 'cure' for breast cancer, say doctors fr
By Nigel Hawkes, Health Editor The drug Herceptin will revolutionise the way breast cancer is treated and save up to 1,500 lives a year in Britain, according to doctors
thetimes 10:48:00 PM CEST
Overwhelming response to Breast Care Campaign
MaltaIndipendent 11:15:00 AM CEST
Drug halves breast cancer relapse rate for some
reuters 11:58:00 PM CEST
One in nine women will develop breast cancer
expatica 12:50:00 PM CEST
Breast cancer drug hailed A drug that targets only diseased cells has proved astonishingly effective against an aggressive form of early breast cancer — a long-sought breakthrough that has doctors talking about curing thousands of women each year in this country alone.
usaToday 11:04:00 PM CEST
Story information
7 days before.
Joan Kennedy Recovers From Cancer Surgery Similarity: 0.41
4 days before.
Spice helps to stop the spread of breast cancer Similarity: 0.73
3 days before.
Men lose out in battle for cancer cash Similarity: 0.74
1 day before.
Cancer services 'could merge' Similarity: 0.67
Related Clusters - across languages
fr
"Prestige" : le FIPOL double ses indemnités Similarity: 0.37
Countries
Places
Related People
Support Group (2)
Josie Muscat (1)
James Group (3)
Gabriel Hortobagyi (3)
Dana- Farber Cancer Institute (2)
Richard Gelber (1)
James Hospital (1)
Marianne Massa (1)
Harold Burstein (1)
Gertrude Abela (1)
World Breast Cancer Day (1)
Association Against Cancer (1)
Colleen Wilson (1)
Jo Anne Zujewski (1)
Gene Emery (1)
Debbie Saslow (1)
Other Names
Genentech Inc (2)
World Health Organization (1)
Malta Independent (1)
Cancer Society (1)
The selection and placement of stories are determined automatically by a computer program.
This site is a joint project of DG-JRC and DG-Press.
THIS SITE IS STILL WORK IN PROGRESS. THEREFORE PLEASE EXCUSE ANY PROBLEMS!
Please send any comments or suggestions to
This site is a project of the SES Unit of the IPSC, DG-JRC.
The information on this site is subject to a disclaimer.
